Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany.

Authors
  • Kresken, M
  • Leitner, E
  • Brauers, J
  • Geiss, H K
  • Halle, E
  • von Eiff, C
  • Peters, G
  • Seifert, H
Type
Published Article
Journal
European Journal of Clinical Microbiology & Infectious Diseases
Publisher
Springer-Verlag
Publication Date
Jan 01, 2009
Volume
28
Issue
1
Pages
83–90
Identifiers
DOI: 10.1007/s10096-008-0589-0
PMID: 18716808
Source
Medline
License
Unknown

Abstract

Tigecycline is a novel antimicrobial agent for parenteral use encompassing a broad spectrum of bacterial pathogens, including multi-resistant organisms. Here, we report the results of the first nationwide surveillance trial that was conducted in order to evaluate the susceptibility of bacterial isolates to tigecycline in a European country prior to its clinical use. A total of 2,610 Gram-positive and Gram-negative organisms recovered from hospitalized patients were tested. Minimum inhibitory concentrations (MICs) were determined using the microdilution method. All enterococci, staphylococci (including methicillin-resistant Staphylococcus aureus; MRSA), and streptococci tested were tigecycline-susceptible, except one isolate of Staphylococcus haemolyticus. Among the Gram-negative bacteria, 100% of the Escherichia coli isolates (including extended spectrum beta-lactamase [ESBL]-producers) were tigecycline-susceptible, while about 10% of the Enterobacter cloacae and Klebsiella pneumoniae isolates were resistant. Based on the results of this surveillance study, tigecycline may represent a suitable option most notably for the empiric treatment of bacterial mixed infections, including in clinical situations in which multi-resistant organisms are suspected.

Report this publication

Statistics

Seen <100 times